Candidiasis

Candidiasis is an opportunistic mycotic infection caused by yeast species of the genus Candida, most commonly Candida albicans. In veterinary medicine, candidiasis is typically a secondary infection that arises when the normal microbial flora is disrupted or when host immune defenses are compromised. The disease can manifest as superficial infections of the skin, mucous membranes, and gastrointestinal tract, or as systemic, deep-seated infections involving multiple organs. In dogs and cats, candidiasis is relatively uncommon compared to other fungal infections, but it can be severe and life-threatening in immunocompromised patients. The clinical presentation varies widely depending on the portal of entry, the extent of tissue invasion, and the underlying predisposing condition. Systemic candidiasis is characterized by hematogenous dissemination, leading to lesions in the kidneys, heart, eyes, and central nervous system. The disease is classified into mucocutaneous candidiasis (oral, esophageal, gastrointestinal, cutaneous, and vulvovaginal) and systemic candidiasis (candidemia and deep organ involvement).

The primary causative agents are yeast species of the genus Candida, with Candida albicans being the most frequently isolated in veterinary cases. Other pathogenic species include Candida tropicalis, Candida parapsilosis, Candida glabrata, and Candida krusei. These organisms are commensals of the gastrointestinal tract, skin, and mucous membranes of healthy animals. Virulence factors of Candida species include the ability to adhere to epithelial and endothelial cells, morphological transition from yeast to hyphal or pseudohyphal forms, secretion of hydrolytic enzymes (e.g., proteases, phospholipases), and biofilm formation. Transmission is typically endogenous, arising from the animal's own flora, but exogenous transmission via contaminated medical devices or environmental surfaces is possible. Immunosuppression, disruption of mucosal barriers, and alterations in normal flora are critical triggers for invasion and disease.

Candidiasis is reported worldwide in dogs and cats, but it is relatively rare compared to other mycoses. There is no strong breed or sex predisposition, but young animals and those with underlying diseases are more susceptible. In dogs, candidiasis is often associated with immunocompromising conditions such as canine distemper, parvoviral enteritis, or long-term immunosuppressive therapy. In cats, it is frequently seen in association with feline leukemia virus (FeLV), feline immunodeficiency virus (FIV), or chronic corticosteroid use. The incidence is higher in hospitalized patients, especially those with indwelling urinary catheters, intravenous catheters, or receiving broad-spectrum antibiotics. Geographic variation is not significant, as Candida species are ubiquitous. The disease is more common in environments with poor hygiene or in animals with prolonged antibiotic therapy that disrupts normal flora.

The pathogenesis of candidiasis involves a complex interplay between the fungus and the host's immune system. Under normal conditions, intact mucosal barriers, commensal microbiota, and innate immune responses (e.g., neutrophils, macrophages, and antimicrobial peptides) prevent Candida overgrowth. When these defenses are compromised, Candida can adhere to and invade epithelial cells. The transition from yeast to hyphal form enhances tissue invasion and evasion of phagocytosis. Once in the bloodstream, Candida can disseminate to various organs, particularly the kidneys, heart, and brain. The host's inflammatory response, including the release of pro-inflammatory cytokines, can lead to tissue damage and septic shock. In systemic candidiasis, the formation of microabscesses and granulomatous inflammation is common. In mucocutaneous candidiasis, the organism invades the superficial layers of the skin and mucous membranes, causing characteristic white plaques or erythematous lesions.

Predisposing factors for candidiasis include any condition that compromises the immune system or disrupts normal flora. Intrinsic factors include primary immunodeficiencies (e.g., severe combined immunodeficiency), endocrinopathies such as diabetes mellitus, and neoplasia. Extrinsic factors include prolonged use of broad-spectrum antibiotics, immunosuppressive drugs (e.g., corticosteroids, chemotherapy), indwelling catheters (urinary, intravenous), parenteral nutrition, and surgical procedures. In addition, malnutrition, stress, and concurrent viral infections (e.g., FeLV, FIV, canine distemper) increase susceptibility. In the gastrointestinal tract, conditions that alter mucosal integrity, such as inflammatory bowel disease or gastrointestinal parasitism, can predispose to candidiasis. Cutaneous candidiasis is often associated with moist, macerated skin folds or wounds.

Clinical signs of candidiasis vary depending on the site of infection. Mucocutaneous candidiasis may present with oral lesions characterized by white, raised, cottage-cheese-like plaques on the tongue, gums, and buccal mucosa, which may bleed when scraped. Esophageal candidiasis can cause dysphagia, regurgitation, and hypersalivation. Gastrointestinal candidiasis may lead to chronic diarrhea, weight loss, and vomiting. Cutaneous candidiasis appears as erythematous, moist, crusty lesions with a characteristic foul odor, often in intertriginous areas (e.g., skin folds, ears). Systemic candidiasis is associated with fever, lethargy, anorexia, and signs of sepsis. Organ-specific signs include hematuria and pyuria in renal candidiasis, lameness or joint swelling in osteoarticular involvement, and neurological signs (e.g., seizures, ataxia) in central nervous system candidiasis. Ocular candidiasis may cause uveitis, chorioretinitis, or blindness.

Differential diagnoses for mucocutaneous candidiasis include other causes of stomatitis and glossitis, such as calicivirus infection in cats, herpesvirus infection, uremic stomatitis, and eosinophilic granuloma complex. Oral papillomatosis and squamous cell carcinoma should also be considered. For gastrointestinal candidiasis, differentials include inflammatory bowel disease, intestinal parasitism, bacterial enteritis (e.g., Salmonella, Campylobacter), and other fungal infections (e.g., histoplasmosis). Cutaneous candidiasis must be differentiated from bacterial pyoderma, dermatophytosis, and other yeast infections like Malassezia dermatitis. Systemic candidiasis should be distinguished from other systemic mycoses (e.g., cryptococcosis, blastomycosis, histoplasmosis), bacterial sepsis, and protozoal infections such as toxoplasmosis. Key distinguishing features include cytological identification of yeast and pseudohyphae, culture results, and response to antifungal therapy.

The diagnostic approach to candidiasis begins with a thorough history and physical examination, paying close attention to predisposing factors and clinical signs. For mucocutaneous lesions, cytological examination of smears or scrapings is the first step; the presence of budding yeast and pseudohyphae is highly suggestive. Definitive diagnosis is achieved by fungal culture on Sabouraud dextrose agar, which yields cream-colored colonies. For systemic candidiasis, blood cultures are essential, but they may be negative in early or intermittent candidemia. Urine culture is recommended if renal involvement is suspected. Molecular methods such as PCR can detect Candida DNA in blood, tissue, or urine. Imaging (radiography, ultrasonography) may reveal organomegaly or abscesses. Histopathology of biopsy samples with special stains (e.g., Gomori methenamine silver, Periodic acid-Schiff) is the gold standard for tissue invasion. A diagnostic algorithm should include: (1) initial cytology and culture of lesions; (2) blood and urine cultures in suspected systemic disease; (3) imaging to assess organ involvement; (4) histopathology if lesions are accessible; and (5) molecular testing for rapid species identification and antifungal susceptibility.

Hematology may reveal leukocytosis with a left shift, or leukopenia in severe immunosuppression. Anemia may be present in chronic cases. Serum biochemistry often shows non-specific changes such as hyperglobulinemia, hypoalbuminemia, and elevated liver enzymes (ALT, ALP) if hepatic involvement occurs. In renal candidiasis, azotemia (elevated BUN and creatinine) and hyperphosphatemia may be observed. Urinalysis may show hematuria, pyuria, and the presence of yeast cells on sediment examination. Blood gas analysis may reveal metabolic acidosis in septic patients. Specific biomarkers such as C-reactive protein (CRP) may be elevated. Serological tests for anti-Candida antibodies or antigens (e.g., mannan, beta-D-glucan) are available but not widely used in veterinary medicine. PCR assays for Candida species are increasingly available and can provide rapid, sensitive detection.

Radiography of the thorax and abdomen may reveal organomegaly (e.g., hepatomegaly, renomegaly) or evidence of pneumonia if pulmonary involvement occurs. Ultrasonography is useful for evaluating the kidneys, liver, and spleen for abscesses or architectural changes. Echocardiography may be indicated if vegetative endocarditis is suspected, as Candida can cause valvular lesions. Computed tomography (CT) and magnetic resonance imaging (MRI) are valuable for detecting central nervous system lesions, such as microabscesses or granulomas. Endoscopy is essential for evaluating esophageal and gastric candidiasis, allowing direct visualization of white plaques and collection of biopsy samples.

Cytological examination of smears from lesions, urine, or bronchoalveolar lavage fluid typically reveals oval, budding yeast cells (3-6 µm) and, in invasive forms, pseudohyphae or true hyphae. Gram stain, Wright-Giemsa, or periodic acid-Schiff (PAS) stain can highlight the organisms. Histopathology of biopsy specimens shows yeast and hyphal forms within tissues, often accompanied by neutrophilic or granulomatous inflammation. In systemic candidiasis, microabscesses and necrosis are common in affected organs. Special stains such as Gomori methenamine silver (GMS) and PAS are essential for visualizing the organisms in tissue sections. The presence of tissue invasion is the definitive criterion for invasive candidiasis.

Treatment of candidiasis involves addressing the underlying predisposing factors and administering systemic antifungal therapy. For mucocutaneous infections, topical therapy with clotrimazole or miconazole may be effective, but systemic therapy is often required. The drug of choice for systemic candidiasis is fluconazole (5-10 mg/kg PO q12-24h) due to its excellent bioavailability and tissue penetration. Amphotericin B (0.5-1.0 mg/kg IV q48h, up to a cumulative dose of 8-12 mg/kg) is reserved for severe, refractory cases, but it is nephrotoxic and requires careful monitoring. Voriconazole (4-6 mg/kg PO q12h) and caspofungin (2 mg/kg IV q24h) are newer options but are expensive and not routinely used in veterinary practice. In addition, supportive care includes fluid therapy, nutritional support, and management of sepsis. Surgical debridement of infected tissues or removal of infected catheters is essential. The duration of therapy is typically 2-4 weeks for mucocutaneous infections and 4-8 weeks or longer for systemic disease, with repeat cultures to document clearance.

The prognosis for mucocutaneous candidiasis is generally good if the underlying predisposing factor is corrected and appropriate antifungal therapy is administered. However, systemic candidiasis carries a guarded to poor prognosis, especially in immunocompromised patients. Mortality rates for systemic candidiasis in dogs and cats are high, ranging from 50% to 80%, despite treatment. Negative prognostic indicators include persistent candidemia, multi-organ involvement, and failure to resolve the underlying immunosuppressive condition. Early diagnosis and aggressive therapy improve the chances of survival, but recurrence is possible if predisposing factors remain.

Follow-up monitoring is crucial to ensure resolution of infection and to detect recurrence. For mucocutaneous candidiasis, re-evaluation of lesions should be performed every 1-2 weeks until resolution. For systemic candidiasis, repeat blood cultures should be obtained every 48-72 hours until negative. Serial monitoring of renal function (creatinine, BUN, urinalysis) is essential if amphotericin B is used. Liver enzymes should be monitored if azole antifungals are administered. Imaging studies may be repeated to assess resolution of organ lesions. Long-term management includes addressing any underlying immunosuppressive conditions and minimizing the use of broad-spectrum antibiotics and indwelling catheters.

Pearls: (1) Always consider candidiasis in immunocompromised patients with unexplained fever or lesions. (2) Cytology is a rapid, inexpensive diagnostic tool; look for budding yeast and pseudohyphae. (3) Fluconazole is the first-line systemic antifungal due to its safety profile. (4) Remove or replace any indwelling catheters in suspected systemic candidiasis. Pitfalls: (1) Do not rely solely on blood cultures, as they may be negative in early disease. (2) Avoid using amphotericin B without monitoring renal function. (3) Do not discontinue antifungal therapy prematurely; ensure a full course. (4) Failure to identify and correct the underlying predisposing factor will lead to treatment failure.

Based on Plumb's Veterinary Drug Handbook, the following protocols are recommended: Fluconazole: 5-10 mg/kg PO q12-24h for 2-4 weeks (mucocutaneous) or 4-8 weeks (systemic). Amphotericin B (deoxycholate): 0.5-1.0 mg/kg IV q48h, diluted in 0.45% saline and administered over 4-6 hours, with saline diuresis to reduce nephrotoxicity; cumulative dose 8-12 mg/kg. Lipid-complex amphotericin B: 1-3 mg/kg IV q48h, less nephrotoxic. Voriconazole: 4-6 mg/kg PO q12h for 2-4 weeks. Caspofungin: 2 mg/kg IV q24h for 2-4 weeks. For topical therapy, clotrimazole 1% cream or miconazole 2% cream applied to lesions q12h. Adjust dosages in renal or hepatic impairment: fluconazole dose should be reduced in renal insufficiency (e.g., 50% reduction if GFR < 50%). Contraindications: azoles are teratogenic in pregnancy; amphotericin B is contraindicated in patients with pre-existing renal disease. Drug interactions: fluconazole can increase levels of cyclosporine, phenytoin, and warfarin.

Evidence-based literature on candidiasis in veterinary medicine is limited, but several studies and reviews provide guidance. A retrospective study by Pressler et al. (2003) reported that systemic candidiasis in dogs is often associated with immunosuppressive therapy and carries a high mortality rate. Another study by Malik et al. (2002) described successful treatment of feline nasal candidiasis with fluconazole. Consensus guidelines from the ACVIM (American College of Veterinary Internal Medicine) on fungal infections recommend fluconazole as first-line therapy for candidiasis, with amphotericin B reserved for severe cases. A meta-analysis of human candidiasis suggests that early antifungal therapy improves outcomes, which is likely applicable to veterinary patients. The use of echinocandins (e.g., caspofungin) is supported by case reports in dogs. Overall, the evidence base is weak, and treatment decisions should be individualized based on culture and susceptibility testing when possible.